Место серелаксина в лечении острой декомпенсации сердечной недостаточности: от уменьшения симптоматики к улучшению прогноза

Место серелаксина в лечении острой декомпенсации сердечной недостаточности: от уменьшения симптоматики к улучшению прогноза

Автор: Жиров И.В., Терещенко С.Н.

Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal

Рубрика: Оригинальные статьи

Статья в выпуске: 3, 2015 года.

Бесплатный доступ

В обзоре представлены результаты основных клинических исследований препарата серелаксин - первого лекарственного средства для пациентов с острой сердечной недостаточностью, применение которого в острый период ведёт к улучшению среднесрочного прогноза.

Сердечная недостаточность, острая декомпенсация, серелаксин

Короткий адрес: https://sciup.org/14342795

IDR: 14342795

Список литературы Место серелаксина в лечении острой декомпенсации сердечной недостаточности: от уменьшения симптоматики к улучшению прогноза

  • Mebazaa A., Yilmaz M., Levy Ph. et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine -short version. Eur Heart J 2015 DOI 10.1093
  • Gheorghiade M., Abraham W.T., Albert N.M., Greenberg B.H., O’Connor C.M., She L., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006; 296(18): 2217-26.
  • Gheorghiade M., Pang P.S. Acute heart failure syndromes. J Am Coll Cardiol. 2009; 53(7): 557-73.
  • Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50(8): 768-77.
  • Fonarow G.C., Abraham W.T., Albert N.M., Stough W.G., Gheorghiade M., Greenberg B.H., et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007; 297(1): 61-70.
  • Ronco C., Haapio M., House A.A., Anavekar N., Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52(19): 1527-39.
  • Metra M., Bettari L., Pagani F., Lazzarini V., Lombardi C., Carubelli V., et al. Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. Clin Res Cardiol. 2012; 101 (8): 663-72.
  • Diez J. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions. Am J Cardiovasc Drugs. 2014 Mar 4 .
  • Milo O., Cotter G., Kaluski E., Brill A., Blatt A., Krakover R., et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol. 2003; 92(2): 222-6.
  • Bott-Flugel L., Weig H.J., Uhlein H., Nabauer M., Laugwitz K.L., Seyfarth M. Quantitative analysis of apoptotic markers in human end-stage heart failure. Eur J Heart Fail. 2008; 10(2): 129-32.
  • Biolo A., Fisch M., Balog J., Chao T., Schulze P.C., Ooi H., et al. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail. 2010; 3(1): 44-50.
  • Cleland J.G., Coletta A.P., Buga L., Antony R., Pellicori P., Freemantle N., et al. Clinical trials update from the American Heart Association meeting 2010: eMpHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail. 2011; 13(4): 460-5.
  • Konstam M.A., Gheorghiade M., Burnett J.C. Jr, Grinfeld L., Maggioni A.P., Swedberg K., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297(12): 1319-31.
  • Mebazaa A., Nieminen M.S., Packer M., Cohen-Solal A., Kleber F.X., Pocock S.J., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297(17): 1883-91.
  • Metra M., Cleland J.G., Weatherley B.D., Dittrich H.C., Givertz M.M., Massie B.M., et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. Eur J Heart Fail. 2010; 12(5): 499-507.
  • Teerlink J.R., Cotter G., Davison B.A., Felker G.M., Filippatos G., Greenberg B.H., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013; 381(9860): 29-39
  • Konstam M.A. RELAX-AHF: rising from the doldrums in acute heart failure. Lancet. 2013; 381(9860): 5-6.
  • Hisaw F.L. Experimental relaxation of the pubic ligament of guinea pig. Proc Soc Exp Biol Med. 1926; 23: 661-3.
  • Fevold H.L., Hisaw F.L., Meyer R.K. The relaxative hormone of the corpus luteum. Its purification and concentration. J Am Chem Soc. 1930; 52: 3340-8.
  • Hudson P., Haley J., John M., Cronk M., Crawford R., Haralambidis J., et al. Structure of a genomic clone encoding biologically active human relaxin. Nature. 1983; 301(5901): 628-31.
  • Bathgate R.A., Halls M.L., van der Westhuizen E.T., Callander G.E., Kocan M., Summers R.J. Relaxin family peptides and their receptors. Physiol Rev. 2013; 93(1): 405-80.
  • Dschietzig T., Bartsch C., Baumann G., Stangl K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther. 2006; 112(1): 38-56.
  • Dschietzig T., Richter C., Bartsch C., Laule M., Armbruster F.P., Baumann G., et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 2001; 15(12): 2187-95.
  • Stewart D.R., Celniker A.C., Taylor C.A. Jr, Cragun J.R., Overstreet J.W., Lasley B.L. Relaxin in the peri-implantation period. J Clin Endocrinol Metab. 1990; 70(6): 1771-3.
  • Khan-Dawood F.S., Goldsmith L.T., Weiss G., Dawood M.Y. Human corpus luteum secretion of relaxin, oxytocin, and progesterone. J Clin Endocrinol Metab. 1989; 68(3): 627-31.
  • Dschietzig T., Teichman S., Unemori E., Wood S., Boehmer J., Richter C., et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009; 15(3): 182-90.
  • Metra M., Ponikowski P., Cotter G., Davison B.A., Felker G.M., Filippatos G., et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J. 2013; 34(40): 3128-36.
  • Metra M., Cotter G., Davison B.A., Felker G.M., Filippatos G., Greenberg B.H., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013; 61(2): 196-206.
  • Teerlink J. et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009; 373: 1429 -1439.
  • Costanzo M., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Amer Coll Cardiol. 2007; 49: 675-683
  • Lucas C., et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Amer Heart J. 2000; 140: 840-847.
  • Metro M. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail. 2010; 12: 1130-9.
  • Teerlink J., et al. Vasodilators in acute heart failure (AHF): does blood pressure matter? Results from Pre-Relax-AHF. J Cardiac Failure. 2009; 15: 74-9.
  • Gheorghiade M., Follath F., Ponikowski P., Barsuk J.H., Blair J.E., Cleland J.G., et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010; 12(5): 423-33.
  • Ambrosy A.P., Vaduganathan M., Huffman M.D., Khan S., Kwasny M.J., Fought A.J., et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail. 2012; 14(3): 302-11.
  • Bettencourt P., Azevedo A., Pimenta J., Frioes F., Ferreira S., Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004; 110(15): 2168-74.
  • Januzzi J.L. Jr, Filippatos G., Nieminen M., Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012; 33(18): 2265-71.
  • Lassus J., Harjola V.P., Sund R., Siirila-Waris K., Melin J., Peuhkurinen K., et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NTproBNP. Eur Heart J. 2007; 28(15): 1841-7.
  • Терещенко С.Н., Жиров И.В. Острая сердечная недостаточность. В кн.: Руководство по кардиологии. Под редакцией Чазова Е.И. -М.: «Практика», 2014 -Т. 4. -С. 137-191.
  • Косицына И.В., Терещенко С.Н., Ускач Т.М., Голубев А.В., Насонова С.Н., Жиров И.В. Новые возможности в лечении острой декомпенсированной сердечной недостаточности.//Кардиологический вестник. -2014. -Т-IX. -№ 2. -С.68-75.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp